• home
  • about us
    • the advantage
    • key facts
    • where we are
    • where we invest
    • management team
    • funds
  • portfolio
    • companies
    • CEOs
  • news
  • investments
    • focus
      • prevention & nutraceuticals
      • medical foods OTC, Rx
      • enabling technologies
      • brands & channels
      • diagnostics
    • criteria
    • process
  • your business
  • careers
  • contact us
    • the bahamas
    • united kingdom
    • china
    • new zealand
transforming inventions
into competitive advantages
Justus Homburg, Vital Foods:
"Inventages has been a long-time supporter of Vital Foods and their commitment to the company and its technology as well as open communication, vision, flexibility, process and critical and ..."
Martin Welschof, Opsona:
"Inventages had the vision and courage to support Opsona's quest to develop first in class and revolutionary treatment option targeting key structures of the innate immune system. ..."
Arvind Sridharan, Horizon:
"Inventages has set itself high standards - and naturally expects the same from its portfolio companies. ..."
Geoff Allison, Tanfield Foods:
"Inventages, since the outset have actively encouraged and supported our growth plans. ..."
Pierre Peteuil, Traceo:
"Inventages invests in a long term strategy necessary for innovation. ..."
Sven Thormahlen, Mucovax:
"At Inventages people share our passion for the development of our innovative products. ..."
Holger Kunze, Accera:
"Working with Inventages has been very productive. ..."
Paul Hartung, Cognoptix:
"Inventages has been a strong supporter in realizing the Cognoptix vision. ..."
Yan Hervy, Velle Russia:
"Over the last year of cooperation, Inventages - through the very high caliber of its associates - has been able to challenge positively Velle Russia business from marketing vision to operational ..."
Graham Clarke, ImmunoBiology:
"Investment capital is of course central to create a valuable business but to be successful you need more than just funds from your investors. ..."
Wren Zhang, GC-Rise:
"GC-Rise has received great support and professional help from Inventages since the beginning. ..."
Erik van den Berg, AM-Pharma:
"Inventages has a broad network of excellent service providers and experts and can provide board room access with potential strategic partners. ..."
Daniel Green, Phagenesis:
"Inventages brings talent, imagination and rigor to the process of identifying suitable investments. ..."
Barry Guld, MSI:
"The team at Inventages is the perfect partner for us. ..."
Thomas Warthoe, Atonomics:
"Atonomics' vision and Inventages' early investment emphasize our common belief that new and improved technology can and will impact positively quality of life for most people. ..."

  • 2013-05-07 - Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305, a First-in Class Monoclonal Antibody
    about Opsona...



  • 2013-04-29 - Opsona Therapeutics Limited raises €33 million (USD 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305
    about Opsona...



  • 2013-04-09 - Cognoptix reaches halfway point of pre-pivotal clinical trial of drug/device test designed to identify Alzheimer’s disease via beta amyloid signature in the eyes
    about Cognoptix...



  • 2013-03-04 - Appointment of new CEO - Justus Homburg joins Vital Foods
    about Vital Foods...



  • 2013-02-28 - Cognoptix begins pre-pivotal clinical trial of its drug/device test designed to identify Alzheimer's disease
    about Cognoptix...


Terms Print Top
© 2013 Inventages